Eli Lilly (LLY) brushed off concerns about the impact of CVS Health's (CVS) decision to drop coverage of Lilly's Zepbound weight-loss drug from some of its health plans while retaining rival Novo Nordisk's (NVO) Wegovy.
"We're not surprised that this kind of thing was announced," Lilly Chief Executive David Ricks said on an earnings conference call Thursday, according to a FactSet transcript. "We're not interested at all in one-of-one deals of reducing access and choice for doctors and patients."
CVS did not immediately reply to MT Newswires' request for comment.
Lilly shares were up 2.4% in recent premarket activity Friday after closing nearly 12% lower Thursday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.